Podcasts about Carl Zeiss

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

Sebastian Frericks, Head of Investor Relations atCarl Zeiss Meditec AG, presents theQ1 2024/25 financial results and discusses revenue growth, market challenges, and future strategies.At the start of the fiscal year,Carl Zeiss Meditec recorded a 3% revenue growth, primarily driven by theDOCTER OPTICS (DO) acquisition. However, underlyingorganic momentum remained negative, as anticipated. The company had previouslyguided for this decline in December, signalling a temporary headwind due to specific market conditions.Despite anegative investment climate in China, with hospitals delaying purchases while awaiting stimulus measures, Carl Zeiss Meditec has shown resilience. Last year's strong post-pandemic delivery phase also meant that this quarter faced a challenging comparison base, but the company has navigated these challenges with determination.Another key issue was theprice decline in intraocular lenses (IOLs) due to China'sVolume-Based Procurement (VBP) regulations, impacting pricing power in this segment. Despite these headwinds, thecompany's order backlog grew by nearly €100 million, reaching€382 million in Q1, signalling stronger demand for future quarters.Notably, the company reported itsfirst consistent order turnaround in 12–18 months, boosting confidence that organic performancehas bottomed out and is set for an upturn.Due to theweak organic performance and product mix effects, particularly lower sales ofhigh-margin surgical microscopes, Carl Zeiss Meditec'sEBITDA declined at the start of the fiscal year. However, theophthalmology division grew by 7%, primarily driven by theDO acquisition. This strategic growth, despite the decline, demonstrates thecompany's forward-thinking approach.Similarly, themicrosurgery division faceda 7.8% organic decline, mainly because of tough comparisons against a strong prior-year period driven by backlog clearance. However, the company is ramping up sales for the next-genKINEVO neurosurgical microscope, expected todrive recovery in the coming quarters.One of thebiggest developments in Q1 2024/25 was theearly approval of VISUMAX 800 in China. Thislatest-generation femtosecond laser system revolutionizes laser vision correction by enabling alenticular cut in 6–8 seconds, significantly enhancingsafety, automation, and patient comfort.Carl Zeiss Meditecmaintains a conservative full-year outlook, citinggeopolitical risks and macroeconomic uncertainties in China. However, stabilization signs insurgical procedure volumes suggest the marketmay have reached its lowest point.Key growth drivers moving forward:✅Stronger order backlog supporting future revenue momentum✅VISUMAX 800 launch in China & US driving market expansion✅KINEVO 900S rollout in neurosurgery boosting high-margin sales✅Potential public stimulus measures in China as a wildcard for upsideFrom amid-term perspective (3–5 years), Carl Zeiss Meditec aims forEBITDA margin recovery to 16–20%, depending onmarket recovery and product adoption.Carl Zeiss Meditec'sQ1 2024/25 results highlight atransitional phase—whileshort-term challenges persist, strategic investments in innovation and operational efficiency position the company forstronger performance ahead.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

CEO Presentation: Carl Zeiss Meditec AG Q1 2024/25 Financial PerformanceIn this comprehensive presentation, the CEO of Carl Zeiss Meditec AG delves into the company's performance during the first quarter of the 2024/25 fiscal year, highlighting a modest increase in revenue. The discussion begins with an overview of the financial results, where the CEO reports a slight revenue growth compared to the same period in the previous year. This growth is attributed to steady demand across key product lines and strategic market expansions.The CEO emphasizes the performance of the Ophthalmic Devices segment, which experienced a notable uptick in sales. This success is largely due to the strong market acceptance of their innovative surgical and diagnostic products. The company's commitment to advancing ophthalmic technology has reinforced its position as a leader in this sector.Despite challenges, the Microsurgery segment demonstrated resilience. The CEO acknowledges a slight revenue decline, attributing it to temporary market fluctuations. However, he anticipates a rebound in the upcoming quarters. The company's efforts to strengthen this segment through targeted marketing strategies and introducing new products designed to meet evolving customer needs are a testament to its resilience and commitment to growth.The presentation also covers the company's regional performance. The Asia-Pacific region emerged as a significant contributor to revenue growth, driven by increased demand in countries such as China and India. The company maintained stable performance in the Americas and EMEA regions, with ongoing initiatives to capture additional market share.Innovation remains a cornerstone of Carl Zeiss Meditec's strategy. The CEO discusses recent investments in research and development, focusing on cutting-edge technologies that enhance diagnostic accuracy and surgical outcomes. These innovations are expected to drive future growth and provide a competitive edge in the medical technology landscape.Underlining its commitment to sustainability and corporate responsibility, the company is actively reducing its environmental footprint through energy-efficient manufacturing processes and sustainable product designs. Initiatives promoting diversity and inclusion within the workforce are also underway, fostering a culture that values varied perspectives and experiences. These efforts are a source of pride for the company and its stakeholders.Looking ahead, the CEO outlines the strategic priorities for the remainder of the fiscal year. Key focus areas include expanding the global sales network, accelerating digital transformation efforts, and exploring strategic partnerships to enhance the product portfolio. Despite potential macroeconomic headwinds, the company remains cautiously optimistic about achieving its financial targets.In conclusion, the CEO reiterates Carl Zeiss Meditec's unwavering dedication to delivering value to its stakeholders—shareholders, customers, and patients. By leveraging innovation, operational excellence, and a customer-centric approach, the company aims to successfully navigate the dynamic healthcare environment, always keeping the best interests of its stakeholders at heart▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Hawaiian Eye meeting with guests Paul Singh, MD, Candy Simerson, Jeffrey Goldberg, MD, PhD, and Roger Goldberg, MD, MBA. Welcome to the Eyeluminaries podcast :02 Review of episode 30 3:23 Intro of Paul Singh, MD 3:40 What are the future trends in glaucoma you're most excited about? 5:10  What challenges do you see in running your practice that didn't exist in your dad's day? 8:36 You've got a great medical office, a very busy consulting and research practice, you play in a band and you have a young family. What advice would you give others in keeping it all in balance? 12:09 Besides your dad and the two of us, who do you look up to in eye care? 14:45 Singh sings a Funkadesi song 18:16 Intro of Candy Simerson 20:36 When you come into a new practice to consult, what are the most common areas you see where improvement can be made? 21:41 What about the finances? What areas in finances do you see where improvement can be made? 24:27 In your many years in ophthalmology, what are the biggest challenges you've experienced? 26:10 What type of practice should consider a sale to private equity? What type of practice should not? 29:34 What advice would you give a company representative who wants to win business from a big ophthalmology practice? 32:29 Intro of the Goldbergs 36:25 Jeff Goldberg, MD, PhD 36:50 Roger Goldberg, MD, MBA 37:21 Jeff, why glaucoma instead of retina? 38:43 Roger, why retina instead of glaucoma? 39:37 Mazzo discusses neuroprotection in retina and glaucoma. 41:14 What is entrepreneurship like today? What's your advice? What is challenging and what is positive? 43:10 Mazzo discusses being realistic about innovations. 48:30 What is private practice like today? 49:31 How do cornea specialists better understand glaucoma specialists? 53:05 How do cornea specialists better understand retina specialists? 54:13 Tell us about emmecell. 55:50 Preview of episode 32 59:19 Give us your feedback 1:00:18 Thanks 1:00:30 Jeffrey Goldberg, MD, PhD, is professor and chair of ophthalmology at the Byers Eye Institute at Stanford University and a member of the National Academy of Medicine. Roger Goldberg, MD, MBA, board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society and the American Academy of Ophthalmology. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Candy Simerson is the senior vice president of practice operations at Vision Integrated Partners. I. Paul Singh, MD, is the president of The Eye Centers of Racine & Kenosha, Ltd., founded in 1981 by his father, Dr. Kanwar A. Singh. He is a founding member of the band, Funkadesi, a mix of Indo-Afro-Caribbean style music. The band tours the world spreading the message “one family, many children.” We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for the Goldbergs, Simerson and Singh at the time of publication.

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.

Carl Zeiss Meditec AG Elevator Pitch: Key Takeaways Carl Zeiss Meditec AG: Market Leadership and Strategic Outlook Corporate Overview In this engaging elevator pitch, Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, provides a concise yet comprehensive introduction to the company's equity story, market leadership, and growth potential. As one of the world's leading medical technology companies, Carl Zeiss Meditec dominates the fields of ophthalmology and microsurgery, combining innovation with a strong market presence that instils confidence in our investors and stakeholders. - Revenue: Carl Zeiss Meditec generates €2 billion in annual revenue. - Ownership: 59% of the company is owned by Carl Zeiss AG, a global optics and imaging powerhouse. - Business Segments:  -- Ophthalmology: Dominates with innovative solutions across diagnostics, refractive surgery, cataract surgery, and retinal treatments.  -- Microsurgery: Focuses on neurosurgery, spinal surgery, ENT, and plastic/reconstructive surgery, with world-leading visualization systems.  -- Recurring Revenue: Approximately 47% of revenue is recurring, driven by consumables, software, and services, offering stability and margin growth. Market Leadership and Growth Drivers Ophthalmology - Refractive Surgery: ZEISS is a global leader with a 40% market share, offering life-changing solutions like SMILE therapy to treat myopia. - Cataract Surgery: Continues to expand market share with premium intraocular lenses and surgical workflows. - Retinal Surgery: Holds a strong #2 position globally, recently enhanced by the DORC acquisition. Microsurgery - ZEISS maintains a 60% global market share in neurosurgical and spinal visualization, delivering cutting-edge intraoperative diagnostic solutions. Geographic Presence and Opportunities - Asia-Pacific: Represents the largest market, driven by high rates of myopia and ageing populations, particularly in China. - US and Europe: Continue to offer significant growth opportunities through portfolio expansion and product rollouts. - Emerging Markets: Heavy investment in India and Southeast Asia positions ZEISS for long-term growth in high-potential regions. Innovation and R&D - R&D Leadership: ZEISS leads the industry in R&D investment, focusing on digitalization, AI, and connected workflows. - Integrated Workflows: The company's unique approach to combining devices, software, and consumables into unified workflows sets it apart, enhancing clinical outcomes and customer loyalty. Strategic Outlook for FY 2024/25 - Challenging Macro Environment: Despite headwinds in the consumer and equipment markets, ZEISS is poised for moderate revenue growth and gradual margin recovery. - Product Launches: New offerings like the KINEVO 900 S and VISUMAX 800 are expected to drive growth in the second half of FY25. - DORC Integration: The full-year consolidation of the DORC acquisition provides significant opportunities in the retinal surgery market. Addressing the Myopia Pandemic ZEISS addresses the growing global prevalence of myopia, which is projected to affect 50% of the world's population by 2050. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Introduction to Carl Zeiss Meditec AG by Sebastian Frericks, Head of Investor Relations Sebastian Frericks, Head of Investor Relations, delivered an engaging and insightful presentation on Carl Zeiss Meditec AG, a globally recognised leader in Ophthalmology and Microsurgery. This presentation comprehensively overviewed the company's market position, key strategies, and future growth drivers. The company achieved €2,089 million in revenue in the 2023/24 fiscal year, with a historically solid EBIT margin of 12%. Carl Zeiss Meditec is a market leader with a 40% share in Refractive Surgery and a growing market share in Surgery Anterior (Cataract). Listed on MDAX and TecDAX, Carl Zeiss Meditec is 59% owned by Carl Zeiss AG, a private optics and technology powerhouse. Key Business Segments Ophthalmology - Revenue Contribution: Comprises 77% of total revenue and focuses on diagnosis, treatment, and surgical solutions. - Key Subsegments: - Chronic Disease Management - Refractive Surgery - Cataract Treatment - Retinal Treatment - Market Leadership: Includes a 40% share in Refractive Surgery and a growing share in Anterior Surgery (Cataract). Microsurgery - Revenue Contribution: Contributes 23% of revenue, focusing on high-tech surgical visualisation for Neurosurgery, ENT, Plastic Surgery, and Dentistry. - Market Leadership: ZEISS dominates the microsurgical market with a 60% global share. Geographic Reach and Structural Tailwinds Regional Insights: - The Asia-Pacific region is a key growth driver, accounting for 26% of revenue, with China as the largest single market. - Other significant regions include the US, Germany, and Southeast Asia. Structural Growth Drivers: - Ageing populations lead to increased cataract surgeries. - Rising myopia prevalence, particularly in Asia, where up to 90% of young people have myopia. - Growing demand for digitalised workflows and premium surgical solutions. Innovation and Strategic Investments R&D Investment: Carl Zeiss Meditec commits 16.7% of revenue to R&D. Key Innovations: - VISUMAX®️ 800: A cutting-edge refractive laser surgery system. - KINEVO®️ 900 S: Neurosurgery platform designed for efficiency and better surgical outcomes. - Digital Solutions: Investments focus on connectivity and integrated workflows to enhance clinical outcomes and customer loyalty. Key Growth Drivers - Expansion in emerging markets, including India and Southeast Asia. - Increasing demand for premium intraocular lenses (IOLs) for cataract surgeries, forecasted to grow in unit and revenue share. - Advancements in refractive laser surgery driven by rising global myopia rates. Future Outlook FY 2024/25 Goals: - Moderate revenue growth supported by product launches, including VISUMAX®️ 800 approvals in key markets like the US and China. Macroeconomic Challenges: - Includes constrained consumer spending and investment climates. Profitability Targets: - Long-term EBITA margin target of 16-20%. Conclusion Sebastian Frericks closed the presentation by emphasising Carl Zeiss Meditec's unique market position, strong brand, and commitment to innovation as key factors driving sustainable growth and customer loyalty. This strong brand is a testament to the company's reputation for quality and reliability. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Q&A with Carl Zeiss Meditec AG's Head of Investor Relations, Sebastian Frericks China Market and Recovery Expectations Update on China's Refractive Market and Recovery Expectations for 2024 Market Context: Carl Zeiss Meditec remains the leading player in China's refractive laser surgery market, having experienced over a decade of growth at a CAGR exceeding 20%. However, since China's reopening post-COVID in 2023, the market has faced challenges, including a shift to lower-cost procedures and reduced patient traffic. Utilization rates for installed laser systems declined in the high single digits during late 2024. Seasonality: The refractive business is seasonal, with peaks during Lunar New Year (January-February) and the summer vacation period (July-August). Outlook: A turnaround is expected in the second half of fiscal year 2024/25 with the rollout of the VisuMax 800, an advanced refractive laser platform offering faster and more precise procedures. Despite the current cautious macroeconomic environment, strong indications of clinic demand point to potential growth in late 2025. Trends in Downtrading from SMILE to LASIK in China Observations on Shifts in Procedure Preferences: - Market Shift: The weak consumer environment has shifted preferences from the minimally invasive SMILE therapy to less expensive LASIK procedures. Previously, SMILE accounted for 80% of treatments, but this mix has shifted to 65-70% SMILE and 30-35% LASIK. - Revenue Impact: This mix change has significantly impacted revenue, as SMILE procedures generate higher margins. - Strategic Response: The upcoming VisuMax 800 platform aims to improve the mix by introducing higher-value consumables and addressing the changing consumer landscape. Impact of Volume-Based Procurement (VBP) on IOL Volumes How Has VBP Affected the Intraocular Lens (IOL) Business? VBP Rollout: The Chinese government's volume-based procurement (VBP) system has lowered intraocular lens prices, resulting in significant price reductions across the value chain. While this has pressured margins, volume increases have partially offset the revenue impact. Long-Term Opportunity: With an ageing population and high cataract prevalence, the Chinese market for IOLs has substantial untapped potential. The company expects affordability improvements to drive long-term growth. APAC (Excluding China) Performance Market Dynamics in APAC Regional Highlights: Southeast Asia, including Vietnam, Indonesia, Malaysia, and Singapore, shows strong growth in refractive laser and cataract procedures. India: Economic growth and wealth creation are expected to significantly expand the middle-class market, increasing demand for elective procedures. The company has been directly present in India for over 30 years and is optimistic about its long-term potential. Conclusion Sebastian Frericks highlights Carl Zeiss Meditec AG's resilience amid market challenges, emphasizing the company's strategic positioning, leadership in innovation, and long-term growth potential across global markets. Despite short-term headwinds in China, the company remains optimistic about recovery and expansion opportunities driven by advanced technologies and strong market presence. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Q&A with Carl Zeiss Meditec AG's Head of Investor Relations, Sebastian Frericks US Refractive Market Performance and Competitive Landscape Has refractive competition increased in 2024, particularly from J&J's ELITA or Staar Surgical? - J&J's ELITA: While J&J has entered some markets with their ELITA system, it has yet to gain significant traction in major markets like the US and China due to regulatory hurdles and limited product features. Notably, the system lacks approval for its SILK procedure, which is positioned as a competitor to ZEISS's SMILE therapy. - Staar Surgical: The overlap between ZEISS's laser-based refractive solutions and Staar Surgical's ICL (implantable collamer lens) business is minimal. ICLs cater to niche cases, such as high myopia corrections, where laser-based therapies have limitations. ZEISS maintains a competitive edge in broader applications due to its extensive track record and safety profile, with over 10 million SMILE procedures performed globally. - Strategic Positioning: ZEISS is poised to strengthen its competitive edge with the upcoming rollout of the VisuMax 800, a more advanced platform designed to enhance procedure speed, precision, and patient outcomes. How is your US refractive business performing amid reports of soft demand? - Market Trends: The US market has faced a decline in refractive procedure volumes in 2024 due to high interest rates and reduced consumer spending capacity. Unlike Europe or Asia, a large proportion (approximately 65%) of US refractive procedures are financed, making the market particularly sensitive to macroeconomic conditions. - Outlook: Despite the challenges, the US refractive market holds significant potential. The market size remains underdeveloped relative to historical highs, with 700,000-800,000 annual procedures, far below its peak. ZEISS's technology, particularly the minimally invasive SMILE therapy, is well-positioned to capitalize on market recovery as economic conditions improve and consumer confidence returns. What's your outlook for US equipment sales recovery after Q3 order trends? Stabilization: US equipment sales began stabilizing in Q3 FY24, with improving order entries and a book-to-bill ratio above 1 in the months preceding fiscal year-end. Early trends in FY25 continue to show positive momentum. Growth Drivers: ZEISS is optimistic about growth in FY25, driven by the anticipated FDA approval of the VisuMax 800 platform in mid-2025. The new platform is expected to attract significant demand from clinics aiming to upgrade their technology and enhance patient offerings. What feedback are you getting on the ZEISS cataract workflow? - Market Reception: The ZEISS cataract workflow continues to be well-received, offering a comprehensive and integrated solution for cataract treatment. Feedback highlights the value of combining diagnostic imaging, surgical planning, and premium IOLs (intraocular lenses) within a single platform. Conclusion Sebastian Frericks highlights Carl Zeiss Meditec AG's resilience amidst market challenges, emphasizing the company's strategic initiatives and leadership in innovation. With advanced products like the VisuMax 800 and comprehensive cataract workflows, ZEISS is well-positioned for recovery and long-term growth in the US market. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Strategic Developments and Market Expansion at Carl Zeiss Meditec AG Overview Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, discusses the company's strategic initiatives and recent acquisitions, focusing on the US market rollout of QUATERA 700, the impact of the DORC acquisition, and feedback on the integrated ZEISS cataract workflow. This comprehensive analysis underscores ZEISS's efforts to expand its market potential and strengthen its leadership in ophthalmology and vitreoretinal surgery. Strategic Initiatives and Rollouts Status of QUATERA 700 Rollout and Its Impact on Cataract Surgical Plans QUATERA 700 Introduction: Launched in 2022, the QUATERA 700 fills a critical gap in ZEISS's portfolio as an advanced phacoemulsification (phaco) system for cataract surgery. Challenges: Initial sales have been modest due to delays in obtaining approvals for complementary intraocular lenses (IOLs), particularly premium lenses essential for competitive bundled offerings. Future Plans: ZEISS is heavily investing in R&D to enhance the system's features, accessories, and integration capabilities. The company targets midterm market share gains by leveraging QUATERA's capabilities alongside its broader cataract product suite. Impact of the DORC Acquisition on the Vitreoretinal Market Strategic Fit: The acquisition of Dutch retinal surgery specialist DORC in 2023 has positioned ZEISS as a global leader in vitreoretinal solutions. Opportunities in the US: DORC's established customer base provides ZEISS with an entry point for promoting its IOLs and other complementary products. This synergy is expected to strengthen ZEISS's position in the US market. China Expansion: With its extensive presence and long-standing relationships in China, ZEISS is accelerating DORC's market penetration, leveraging local expertise and distributor networks. Future Integration: The acquisition enables ZEISS to create a comprehensive retinal workflow, combining diagnostic imaging, surgical microscopes, and consumables for improved clinical outcomes. Feedback on ZEISS Cataract Workflow Customer Feedback: The integrated ZEISS cataract workflow has received highly positive feedback for its ability to streamline surgical preparation, reduce complications, and enhance patient outcomes. Efficiency Gains: Studies indicate a 40-50% reduction in surgery preparation and setup time, alongside measurable time savings during procedures due to reduced complications. Market Positioning: ZEISS's fully connected ecosystem of devices and software is becoming the industry standard, setting it apart from competitors offering standalone solutions. Market Potential and Synergies Cross-Selling Opportunities: DORC's retinal customer base offers significant cross-selling potential for ZEISS's cataract solutions, including IOLs and surgical microscopes. Conclusion Carl Zeiss Meditec AG's strategic rollouts, including QUATERA 700 and the integration of DORC, showcase the company's commitment to innovation and market expansion. With a strong focus on delivering comprehensive solutions and leveraging synergies across its portfolio, ZEISS is well-positioned to capitalize on the growing demand in the global ophthalmology and vitreoretinal surgery markets. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Financial and Strategic Outlook: Insights from Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG US Equipment Sales and Market Dynamics Why Were US Equipment Sales, Especially in Microsurgery, Weak in Q3? Market Context: Weakness in microsurgery sales was driven by the late product cycle of older equipment and the launch of the new KINEVO 900 S neurosurgical platform in October 2024. Transition periods between product generations are typically slower. Financing Challenges: Private equity-backed clinics in the US, a significant customer segment, delayed investments due to high interest rates and expectations of an economic turnaround. Recovery Outlook: With the launch of KINEVO 900 S and early stabilization in order entries at the start of FY25, ZEISS anticipates returning to growth in the US market by 2025. Cost-Cutting Plans and Margin Impact Can You Summarize Your Cost-Cutting Plans and Their Impact on Margin Goals? Background: R&D expenses peaked at 17% of sales in FY22 due to investments in digitalization, AI, and cloud-based infrastructure. These investments have built a robust ecosystem of integrated solutions. Optimization Strategy: Adjusted R&D prioritization by focusing on high-impact products. Implemented more responsive planning tools to align R&D investments with market conditions. Reduced or slowed down investments in areas with longer monetization timelines or less immediate commercial potential. Impact on Margins: These adjustments aim to improve productivity and preserve innovation while maintaining ZEISS's leadership as the most R&D-intensive company in the ophthalmology industry. Bridging 2024 Guidance to 2025 Profitability How Do You Bridge 2024 Guidance to the Profitability Step-Up Expected in 2025E? Drivers of Recovery: -Full-year contribution from the DORC acquisition. -Recovery in the Chinese market from inventory destocking. -Continued cost efficiencies in R&D and sales operations. -Stabilized equipment sales and new product launches, including the KINEVO 900 S and QUATERA 700. Macro Conditions: While macroeconomic uncertainty persists, ZEISS expects a gradual improvement in consumer sentiment and demand across key markets. Profitability Targets: The company targets an EBIT margin recovery of 16-20%, depending on macroeconomic developments. R&D Strategy Under Cost Reduction Plan What Is Your R&D Strategy Under the Cost-Reduction Plan, and Where Will Savings Occur? Digital Investments: With foundational investments in cloud infrastructure complete, future spending will focus on developing applications and monetizable use cases. Integration of DORC: Streamlined development plans across cataract and retinal product lines, leveraging synergies from the DORC acquisition. Portfolio Focus: Narrowed the portfolio of premium IOLs to concentrate on high-potential products with the best commercial return. Conclusion With a clear focus on profitability, innovation, and market recovery, Carl Zeiss Meditec AG is well-positioned for long-term growth. The company's strategic initiatives, including the launch of advanced products like the KINEVO 900 S and optimized R&D investments, highlight its resilience and ability to adapt to evolving market dynamics. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28  Bausch + Lomb acquires Elios Vision 2:07  ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00  Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31  Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.

In this comprehensive financial presentation, Dr. Markus Weber, President and CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditec AG, review the company's performance for the fiscal year 2023/24. The presentation addresses a slight revenue decline, the achievement of adjusted EBIT forecasts, and strategic initiatives aimed at future growth. Key Financial Highlights for Fiscal Year 2023/24 Revenue Performance Revenue slightly declined compared to the previous fiscal year, primarily due to market challenges in North America and a delayed peak season for refractive surgeries in China. Adjusted EBIT Despite the revenue decline, the company achieved its adjusted EBIT forecast, demonstrating effective cost management and operational efficiency. Strategic Highlights and Market Dynamics Market Challenges Despite weaker demand in North America and a slower-than-expected start to the peak season for refractive surgeries in China, the company's resilience was evident. These challenges, while impacting overall revenue, did not deter our commitment to delivering value to our stakeholders. Cost Management Proactive measures in cost control, particularly in sales and marketing, contributed to maintaining profitability despite market headwinds. Outlook for Fiscal Year 2024/25 Revenue Projections The company anticipates renewed growth in the upcoming fiscal year, with revenue expected to rebound as market conditions improve. EBIT Margin Targets Carl Zeiss Meditec AG maintains its target of achieving an EBIT margin above 20%, focusing on operational efficiency and strategic market positioning. Strategic Initiatives for Future Growth Innovation and Product Development Continued investment in research and development to introduce advanced medical technologies, enhancing the company's competitive edge. Market Expansion Strategic efforts to expand market presence in emerging regions, leveraging partnerships and localized strategies to drive growth. Conclusion Dr. Weber and Mr. Wehmer reaffirm Carl Zeiss Meditec AG's commitment to innovation, operational excellence, and strategic growth initiatives. Despite the challenges faced in the fiscal year 2023/24, the company is poised for renewed growth and remains dedicated to delivering value to its stakeholders, recognizing their importance in our journey. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this special crossover episode, Eyeluminaries hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are joined live by Susan MacDonald, MD, and Cathleen McCabe, MD, at Eyecelerator 2024 in Chicago, IL. Intro :07 Welcome to the Eyeluminaries podcast 3:14 In this episode 5:02 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 5:11 What started you on this journey to do humanitarian work? 5:30 MacDonald discusses the role of parents in defining of happiness. 10:56 Hovanesian discusses the background of his humanitarian work in Armenia. 11:36 What about the funding of these humanitarian projects? 12:50 What are your stories from doing humanitarian work? 14:11 What advice to do you have for physicians who want to get involved in humanitarian work? 18:55 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 22:23 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 22:50 MacDonald discusses how her humanitarian work began. 23:28 Thank you. 27:05 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 27:51 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 28:42 Visit ACE Global, Cybersight or Operation Sight to get involved. 28:54 Mend the Gap podcast 30:49 Preview of episode 30 32:17 Give us your feedback 32:44 Thanks 33:17 Thoughts 33:27 Visit the ASCRS Foundation to get involved in Operation Sight. 34:20 Thank you for listening! 35:17 Don't forget to like and subscribe to Mend the Gap and Eyeluminaries! 35:39 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on X (formerly Twitter) @Healio_OSN. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Zalando kauft About You, aber wann verkauft man am besten About You? Amazon verkauft jedenfalls Autos, GM stoppt den Taxifahrten-Verkauf und Broadcom verkauft an Apple. Außerdem knackt Musk die 400 Milliarden und Carl Zeiss leidet wie alle. Weihnachten steht an. Bei tonies (WKN: A3CM2W) regnet's Geld. Zumindest der Umsatz regnet. Mit Gewinn ist nicht viel. Mit Wachstum ist nur in den USA viel. Dort gibt's dafür Konkurrenz. Alphabet knackt Quantencomputer-Problem. Wann knackt Quantencomputer das Bitcoin-Problem? Wir klären auf. Diesen Podcast vom 12.12.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, are live from Eyecelerator with Mend the Gap hosts Susan MacDonald, MD, and Cathleen McCabe, MD, discussing their humanitarian work. Welcome to the Eyeluminaries podcast :02 In this episode :31 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 1:00 What started you on this journey to do humanitarian work? 2:18 MacDonald discusses the role of parents in defining of happiness. 7:47 Hovanesian discusses the background of his humanitarian work in Armenia. 8:24 What about the funding of these humanitarian projects? 9:38 What are your stories from doing humanitarian work? 10:59 What advice to do you have for physicians who want to get involved in humanitarian work? 15:43 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 19:11 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 19:38 MacDonald discusses how her humanitarian work began. 20:16 Thank you. 23:49 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 24:39 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 25:30 Visit ACE Global, Cybersight or Operation Sight to get involved. 25:38 Mend the Gap podcast 27:37 Preview of episode 30 29:05 Give us your feedback 29:25 Thanks 30:05 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

For over a decade, an irreplaceable ring laser has been trapped in a cavern 30m below Christchurch port hills. The Carl Zeiss laser was installed in an old World War Two bunker in 1997 until a rockfall after the 2011 Christchurch earthquake sealed the cavern. But now it's been rescued and is fully operational. Professor Jon-Paul Wells is the principal investigator on the ring laser project.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 26 :58 FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42  I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54 First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48 LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57 Intro of Tom Mitro 10:40 Tell us about your journey in ophthalmology 12:38 Tell us about the new dry eye drug from Signal 12. 15:53 How much sensation is on the forehead if the drug is well tolerated? 24:13 What are your thoughts on the current ophthalmology market? 26:01 Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51 Preview of episode 29 33:25 Give us your feedback 34:34 Thanks 34:50 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.

Sebastian Zelger, born in 1988 in Germany, is the CEO of Liqui Moly USA. His early experiences with low-paying and physically exhausting vacation jobs during high school fueled his determination to pursue higher education and a successful career. While studying, Zelger gained hands-on experience at prominent companies like Porsche AG in Stuttgart and Carl Zeiss in Aalen. In 2014, Sebastian joined Liqui Moly as a junior export sales manager, where he underwent two years of intensive training. His hard work and dedication paid off when he was appointed CEO of Liqui Moly USA. At the start of his leadership, the company had just 10 employees and annual sales of $10 million. Over the span of eight years, Zelger successfully grew the business, expanding the team to over 70 professionals and increasing sales to more than $100 million annually. -- Critical Mass Business Talk Show is Orange County, CA's longest-running business talk show, focused on offering value and insight to middle-market business leaders in the OC and beyond. Hosted by Ric Franzi, business partner at REF Orange County. Learn more about Ric at www.ricfranzi.com. 

In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care. Welcome to the Eyeluminaries podcast :10 About Steven Schwartz, MD 2:32 The interview 3:16 Discussion of current innovation in cataract surgery including use of AI, imaging and robotics 4:05 Discussion on Schwartz's involvement in Neurotech MacTel cell-based treatment 6:32 Advances and disappointments in retinal disease treatments? 10:32 How do companies come back from disappointing trial results? 11:07 Why do retina discoveries take so long to develop? 14:31 New dry AMD treatments in development? 15:58  Drug delivery technologies and will retina specialists use them? What do you predict we'll be doing differently in medicine 2 years from now and why? 22:00 What's the difference between a retina and cornea specialist? 23:52 Introduction of Sean Ianchulev, MD, MPH 25:38 The interview 26:29 Impact on Google Glass 30:27 What innovations are you proud of and what projects are you excited about? 35:31 What advice do you have for new entrepreneurs? 42:16 How do you balance your work life and your home life? 45:25 Legends in the field of ophthalmology 47:39 Give feedback at eyeluminaries@healio.com 49:36 Thanks for listening 49:57 Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Steven Schwartz, MD, is the Ahmanson professor in ophthalmology and the chief of the retina division at the UCLA Jules Stein Eye Institute and the director of the Diabetic Eye Disease and Retinal Vascular Center. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Schwartz via email at schwartzpatients@jsei.ucla.edu. You can find Dr. Ianchulev on LinkedIn.  Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schwartz is the co-founder of Horizon Surgical; member on the National Eye Institute Audacious Initiative Scientific executive committee and reports receiving grants from Neurotech, Optos/Nikon, the California Institute of Regenerative Medicine; and investigator fees from Neurotech and Optos/Nikon and the California Institute of Regenerative Medicine.

Sean Comer, Dorian Price, Mik Wanamaker and Mark Radulich review movies currently on streaming services and in theaters: Clockwork Orange/Lolita/Eyes Wide Shut Movie Review! First up is A Clockwork Orange (1971). Then we move on to Lolita (1962). Finally we review Eyes Wide Shut (1999).Stanley Kubrick (July 26, 1928 – March 7, 1999) was an American film director, screenwriter, producer, and photographer. Widely considered one of the greatest filmmakers of all time, his films were nearly all adaptations of novels or short stories, spanning a number of genres and gaining recognition for their intense attention to detail, innovative cinematography, extensive set design, and dark humor.A perfectionist who assumed direct control over most aspects of his filmmaking, Kubrick cultivated an expertise in writing, editing, color grading, promotion, and exhibition. He was famous for the painstaking care taken in researching his films and staging scenes, performed in close coordination with his actors, crew, and other collaborators. He frequently asked for several dozen retakes of the same shot in a movie, often confusing and frustrating his actors. Despite the notoriety this provoked, many of Kubrick's films broke new cinematic ground and are now considered landmarks. The scientific realism and innovative special effects in his science fiction epic 2001: A Space Odyssey (1968) was a first in cinema history, and the film earned him his only Academy Award (for Best Visual Effects). Filmmaker Steven Spielberg has referred to 2001 as his generation's "big bang" and it is regarded as one of the greatest films ever made.While many of Kubrick's films were controversial and initially received mixed reviews upon release—particularly the brutal A Clockwork Orange (1971), which Kubrick pulled from circulation in the UK following a media frenzy—most were nominated for Academy Awards, Golden Globes, or BAFTA Awards, and underwent critical re-evaluations. For the 18th-century period film Barry Lyndon (1975), Kubrick obtained lenses developed by Carl Zeiss for NASA to film scenes by candlelight. With the horror film The Shining (1980), he became one of the first directors to make use of a Steadicam for stabilized and fluid tracking shots, a technology vital to his Vietnam War film Full Metal Jacket (1987). A few days after hosting a screening for his family and the stars of his final film, the erotic drama Eyes Wide Shut (1999), he died from a heart attack at the age of 70.Disclaimer: The following may contain offensive language, adult humor, and/or content that some viewers may find offensive – The views and opinions expressed by any one speaker does not explicitly or necessarily reflect or represent those of Mark Radulich or W2M Network.Mark Radulich and his wacky podcast on all the things:https://linktr.ee/markkind76alsohttps://www.teepublic.com/user/radulich-in-broadcasting-networkFB Messenger: Mark Radulich LCSWTiktok: @markradulichtwitter: @MarkRadulichInstagram: markkind76RIBN Album Playlist: https://suno.com/playlist/91d704c9-d1ea-45a0-9ffe-5069497bad59

Join Journal Club Download my free guide to Internal Bleaching PDF Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin  DOT - Use the Code DENTALDIGEST for 10% off   Qualified at the Royal London Hospital in 1995; achieving a number of awards including The Constance Klein Memorial, The Stafford Millar, and The Malcolm Jenkins Scholarships, The American Association of Endodontics Prize and the Overall Award for Clinical Dentistry. After spending 3 years in oral surgery residency in London and a further year practicing restorative dentistry in London's Harley Street Medical District, he relocated to Cornwall in the extreme southwest of England. Jason practices at Revitalise, Cornwall, UK where his main focus is microscope enhanced adhesive dentistry. His specific interest is direct composite resin artistry and minimally invasive all ceramic restorations and he has presented to dentists locally, nationally and internationally (USA, Canada, Australia, New Zealand, South East Asia and Europe) on this topic. He has given hands on programs in the UK, Europe, Asia, and North America on behalf of GC, Ivoclar, Kerr, Kulzer, Optident, Micerium, Carl Zeiss, Zumax, Global, Velopex and Triodent. He is a European “Key Opinion Leader” for Kulzer and is a member of the European Prosthodontic Advisory Board for GC Europe. Jason is Resident Faculty at The Centre for Esthetic Excellence, Chicago, USA. He is an Accredited International Trainer for Carl Zeiss Dental Academy. Jason is the only European Resident Faculty at Spear Education AZ USA, where he is an instructor in The Composite Program. Jason has achieved Diplomat Status in Restorative Dentistry from the Royal College of Surgeons (England). He is on the Editorial Board of The Russian Journal of Esthetic Dentistry and has published numerous peer-reviewed articles on adhesive and aesthetic dentistry in both the UK and abroad. He is joint author of “Vertical Margin Finish Lines In Fixed Prosthodontics”   

Carl Zeiss Meditec AG 9M 2023/24: Key Takeaways Carl Zeiss Meditec AG: Financial Outcomes for First Nine Months of Fiscal Year 2023/24 Carl Zeiss Meditec AG, a pioneer in medical technology, has disclosed its financial outcomes for the first nine months of the fiscal year 2023/24. Despite encountering modest revenue declines, the company's strategic advancements underscore its resilience in navigating the current challenges and seizing future opportunities within the global healthcare market. Revenue and Earnings Overview Over these nine months, Carl Zeiss Meditec reported a revenue of approximately €1,486.5 million, representing a slight decline of 1.5% compared to the previous year's €1,509.6 million. However, when adjusted for currency and acquisition effects, the revenue saw a minimal positive adjustment of 0.1%, with an organic decline of 5%. The earnings before interest and taxes (EBIT) also saw a significant reduction, falling to €162.7 million from the previous year's €244.9 million, resulting in a decrease in the EBIT margin from 16.2% to 10.9%. CEO's Commentary Dr. Markus Weber, CEO of Carl Zeiss Meditec, conveyed a mixed outlook in his commentary. While he acknowledged the underwhelming performance in the third quarter, he also suggested that market recovery might be on the horizon. Signs of stabilization in the order intake for equipment and consumables could indicate a positive shift. The strategic focus for the upcoming fiscal year will include a blend of immediate resilience tactics and more significant medium-term transformation projects across innovation, manufacturing, and commercialization sectors. Strategic Business Units (SBUs) In detail, the strategic business unit (SBU) of Ophthalmology saw a slight revenue dip of 0.8%, closing at €1,143.0 million. Nevertheless, this unit benefited from the consolidation of the newly acquired retinal surgery company DORC, which added €52.7 million to the revenue. The Microsurgery SBU faced a more substantial revenue drop of 3.9%, primarily due to weakened demand in neurosurgery influenced by cautious investment attitudes, especially noticeable in North America. Regional Performance The EMEA (Europe, the Middle East, and Africa) region exhibited strong growth, increasing by 16.1% to €432.2 million, with significant contributions from Italy, Spain, and France. On the contrary, the Americas saw a notable decline of 13.0%, with North American markets showing reluctance in equipment investment. The Asia-Pacific region experienced a modest downturn of 4.1%, although markets like India and Australia contributed positively. Full-Year Forecast and Strategic Initiatives Carl Zeiss Meditec has adjusted its full-year revenue forecast to roughly €2,000 million, incorporating around €100 million from the DORC acquisition. The expected adjusted EBIT ranges between €225 and €275 million. The company focuses on cost control and efficiency improvements, planning savings in the mid to low double-digit million range, excluding impacts from DORC. These initiatives are part of broader transformation efforts to enhance process efficiency and boost productivity, which are anticipated to gradually restore the EBIT margin towards the target of approximately 20%. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care. •    Welcome to the Eyeluminaries podcast :05 •    Review of episode 25 :46 •    Bausch + Lomb acquires Trukera Medical 1:32  •    CMS proposes cutting physician payments for fifth straight year 4:09 •    FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 •    FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 •    Intro of Cathleen McCabe, MD 13:07 •    American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 •    In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 •    Besides the two of us, who do you admire in ophthalmology? 23:37 •    Tell us about your work, what you do and how you do it. 27:21 •    Preview of episode 27 33:30 •    Thanks 34:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Octane OTF with Euan Thomson, PhD, Barry Kuppermann, MD, Jeffry Weinhuff, Ehsan Sadri, MD, FACS, and a special announcement from Rich Small. Welcome to the Eyeluminaries podcast :05 Review of episode 24 1:38 Intro of Euan Thomson, PhD 2:10 What kind of companies did you like working for the most? 3:14 Can you comment on why adoption of digital solutions is slow and what we can do about it? 4:15 Geographically speaking, what is the area that is doing the best to incorporate new practices in medicine? 6:04  Can you talk about any real-world evidence of the value of using digital ophthalmic workflows being realized today? 7:51 Intro of Barry Kuppermann, MD, PhD 13:06 Before his passing, you had several years where you worked with one of the most beloved people in ophthalmology, Roger Steinert. What it was like to work with him? Tell us a fun or inspiring story. 15:51 What are the biggest challenges today in resident/fellow education? What advice would you give graduating residents/fellows? 18:05 GHEI has a strong research program. Does it get tougher each year to fund quality research? 20:01 Where do you want to see GHEI in the long-term? 23:55 Intro of Jeffry Weinhuff 26:02 Tell us about your career before entering eye care investing. What is different about our unique specialty within healthcare? 26:38 Tell us about the Visionary Ventures Fund. Is it looking for new physician investors? 30:24 Announcement from Rich Small 34:12 What does Neurotech do? 36:56 Intro of Ehsan Sadri, MD, FACS, FAAO 38:48 Doctors frequently get asked to make investments in start-up companies. How do you decide if an investment is a good one? 42:13 What do you think have been the most innovative companies in eye care during your career? 45:09 Preview of episode 26 49:33 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Barry Kuppermann, MD, PhD, is the Roger F. Steinert professor, chair of the department of ophthalmology and director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the department of biomedical engineering at UC Irvine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Ehsan Sadri, MD, FACS, FAAO, is board-certified, fellowship-trained in treating LASIK, cataract and glaucoma surgeries with locations to serve patients in Newport Beach, Santa Ana and Orange. He is also CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund (Visionaryvc.com). Rich Small is CEO and member of the board of directors for Neurotech. Euan Thomson, PhD, is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Jeffry Weinhuff is the chief investment officer and managing partner of Visionary Ventures Fund, a later-stage venture fund focused on investing in drugs and devices for the eye. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Sadri is the CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund. Weinhff is the managing partner of Visionary Ventures Fund. Small is chief executive officer and member of the board of directors for Neurotech. Thomson is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Weinhuff is the managing partner of Visionary Ventures Fund.

Sat, 22 Jun 2024 10:00:00 +0000 https://podcast8f7bd0.podigee.io/284-neue-episode 2e9115cde976ab7bb1ba5ab01d6a1d68 In dieser spannenden Folge 244 des Aktienpodcasts von Modern Value Investing, geben Philipp und Marcel ein umfassendes Update zu den besten REITs für jedes Depot. Unsere Experten beleuchten dabei, warum gerade jetzt der ideale Zeitpunkt ist, um in REITs zu investieren.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS. Brought to you by Johns Hopkins University. •  Welcome to the Eyeluminaries podcast :21 •  Review of episode 23 1:19 •  Blog by John A. Hovanesian, MD, FACS 3:10 •  Merck to acquire EyeBio 4:14 •  FDA approves aflibercept biosimilars Yesafili, Opuviz 6:26 •  Aurion Biotech completes enrollment in phase 1/2 corneal edema cell therapy trial 8:43 •  Intro of Jack Holladay, MD, MSEE 11:10 •  How did you develop a passion for optics? Did you know it was going to be your future? 13:50 •  Holladay's life-threatening situation 16:21 •  Holladay's experience teaching residents 23:50 •  Holladay's optics strategy for improving his golf game 28:33 •  Preview of episode 25 32:25 •  Feedback, questions and guest suggestions at eyeluminaries@healio.com 32:45 Jack T. Holladay, MD, MSEE, FACS, is a clinical professor of ophthalmology at Baylor College of Medicine and retired from clinical ophthalmic practice. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus.

Listen as my friend, Cindy Metrose, Vice President of Strategic Accounts and Zeiss's Digital business in the U.S. and I walk through why Zeiss has continued to be a leader in Eyecare.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Terry Kim, MD, and Stephen Lane about their careers and transitions at Alcon. Brought to you by Johns Hopkins University. Welcome to the Eyeluminaries podcast :21 Review of episode 22 1:27 Intro of Stephen Lane 2:41 Intro of Terry Kim, MD 6:02 Lane: Why retire? What's next? 7:54 Kim: Why the move to the industry? 10:35 Lane: What does a chief medical officer do? What did you learn from the time you went from practice to CMO, and what were some of the surprises? 13:14 Kim: What do you see as some of the challenges you will be facing? 18:19 Lane: What will you miss the most about being a CMO? 21:03 In your experience, how do you navigate transitions in a company and lead without losing focus? 24:22 Preview of episode 24 30:45 Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:34 Thanks for listening 32:08   John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Terry Kim, MD, is a professor of ophthalmology at Duke University Eye Center. Stephen Lane is a founding partner of Associated Eye Care. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement. Brought to you by Johns Hopkins University Welcome to the Eyeluminaries podcast :21 Review of episode 21 :50 Clobetasol propionate ophthalmic suspension 0.05% approved for postop inflammation, pain 2:49 PulseSight Therapeutics launches with focus on non-viral gene therapies 5:31 FDA clears first investigational new drug application for neuropathic corneal pain 7:59 APX3330 ‘promising' oral treatment option for slowing progression of diabetic retinopathy 10:20 H. Dunbar Hoskins Jr., decorated glaucoma specialist, dies 11:55 Intro of Wiley A. Chambers, MD 13:36 What are you most proud of accomplishing in your 36 years at the FDA? 15:54 What about oral therapies for the eye? 17:30 What do you wish you could change? 18:46 What advice would you give an innovator with a new drug idea? 21:31 What's next for Wiley Chambers? Ocular Advisors, LLC 23:17 What has changed since you left the FDA? 25:11 Second annual drug name awards: The Year of Vs and Ys 27:04 “Needs to buy a vowel” award 28:49 “i before e” award 30:23 “Most likely to be misspelled” award 31:44 “Is there a way to pay for it?” award 33:17 The cutesy award 34:29 “Need an award” award 36:10 Preview of episode 23 38:17 Feedback, questions and guest suggestions at eyeluminaries@healio.com 39:59 Thanks for listening 39:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Wiley A. Chambers, MD, is a clinical professor of ophthalmology and adjunct assistant professor of computer medicine at The George Washington University and owner of Ocular Advisors, LLC. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Chambers is the owner of Ocular Advisors, LLC. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Tragische Angriffe im Suezkanal führen paradoxerweise zu steigenden Aktien von Hapag-Lloyd, Maersk und ZIM. Subventionen in China führen logischerweise zu steigenden Aktien. Genauso Übernahmen bei RTL und DocuSign. Carl Zeiss geht shoppen. All for One (WKN: 511000) macht alle fit für SAP und damit sehr viel Umsatz. Wenn jetzt noch der Gewinn nachkommt, hat der Aktienkurs vielleicht auch Bock. Hat jemand Konsumflaute gesagt? Inditex (WKN: A11873) hat nix gehört. Diesen Podcast vom 18.12.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Vance Thompson, MD, Adrienne Graves, PhD, Sean Ianchulev, MD, and Kristen Harmon Igenito, live from AAO Eyecelerator. Welcome to the Eyeluminaries podcast :01 Review of episode 19 1:31 Intro of Vance Thompson, MD 2:13 What is the secret to your success? 3:54 How many fellows have you trained? 5:20 How has having a fellowship training program at Vance Thompson Vision impacted your practice? 6:23 What are the two recently approved products that you are amazed by? 10:02 What is your favorite wine? 12:55 What is your favorite dad joke? 15:25 Intro of Adrienne Graves, PhD 16:59 How does your background help you serve in the companies and non-profits you work with? 19:43 What do strategics do for companies? 24:13 Prescription drug names 25:53 Intro of Sean Ianchulev, MD, MPH 29:45 How do your ideas evolve? 31:53 ·       Who or what inspires you? 45:58 Intro of Kristen Harmon Ingenito 49:39 How is the software different? 51:45 How is market research changing? 55:19 What are you most optimistic about in terms of trends? The most challenging? 57:18 At what point in your life did you decide to work in market research? 59:05 Preview of episode 21 1:02:32 Feedback, questions and guest suggestions at eyeluminaries@healio.com 1:02:40   Adrienne Graves, PhD, serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Kristen Harmon Ingenito has more than a decade of experience in the ophthalmic industry, with nine of those years analyzing data and reporting for Market Scope. Kristen's industry experience began in 2005 at Market Scope, where she served in many roles, including editing, analysis, sales, and marketing. She then joined an ophthalmic patient education software company, where she worked closely with physicians to help drive value in all aspects of their practices, while also training incoming executives on the business of eye care. She returned to Market Scope with added experience to help expand the company's portfolio of products and services. Source: Market Scope Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Vance Thompson, MD, is a board-certified ophthalmologist who specializes in refractive surgery including laser vision correction, implant vision correction and advanced cataract surgery and is the director of refractive surgery at Vance Thompson Vision. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Graves serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. Hovanesian consults widely in the ophthalmic field. Ianchulev is the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Ingenito develops products and provides services to Market Scope. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision.

Season 4 Episode 6 - Analog Combo: Carl Zeiss Biogon ZM 35mm f/2, Leica M4, Kodak TMAX 400 Bringing It All Back Home is back with an Analog Combo — this time focusing on a rented Zeiss Biogon 35mm combined with the classic Leica M4. Tune in & check out this review, the results compared to the Nokton classic — as well as a recap of recent color scans from nicefilmlab. Topics: Carl Zeiss Biogon ZM 35mm f/2, Leica M4, Kodak TMAX 400, ID-11, Lensrentals, Voigtlander 35mm f/1.4 Nokton II, Stock vs. 1+1, nicefilmlab, Wildwood, NJ,  --- Send in a voice message: https://podcasters.spotify.com/pod/show/charles-kershenblatt8/message

In Folge 89 wird gefeiert. Und zwar 100 Jahre Planetarium! Im Frühjahr 1923 wurde bei Carl Zeiss in Jena der erste moderne Planetariumsprojektior in Betrieb genommen und 1925 in München das Planetarium das erste Mal offiziell dem Publikum vorgestellt. Wir haben die Expertin Helen Ahner in den Podcast eingeladen, die uns erzählt, wieso das Planetarium so eine enorme Faszination auf die Menschen ausübt. Außerdem: Ein Anime über Planetarien, eine Diskussion über “Pointerologie” und ganz vie Geschichte über die Faszination des falschen Himmels. Wenn ihr uns unterstützen wollt, könnt ihr das hier tun: https://www.paypal.com/paypalme/PodcastDasUniversum. Oder hier: https://steadyhq.com/de/dasuniversum. Oder hier: https://www.patreon.com/dasuniversum.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York. Welcome to the Eyeluminaries podcast :01 Review of episode 18 :18 Intro of Peter Slack 1:47 How did OSN start? 2:35 When did you get into meetings and where do you see meetings going? 5:40 Where do you see media going? 7:46 How did you end up running the Hawaiian Eye Meeting? 10:53 Intro of Greg Kunst 13:59s What will be the biggest challenges introducing a new paradigm for a traditionally surgical disease? 14:52 What can you tell us about Aurion's plans for cell therapy in other front and back of the eye disease, in addition to endothelial cell disease? 17:04 What should I be telling my patients who have future need for endothelial keratoplasty? 19:17 What is the status of Aurion in Japan? Is the competition on the horizon? 22:13 Intro of Rich Small 25:53 Why are you excited about the Encapsulated Cell Therapy Platform? 27:12 Why MacTel? 31:52 What is the status of the Neurotech BLA? 32:26 ·       Give us a good Jim Mazzo story 34:38 Intro of Uday Devgan, MD, FACS, FRCS(Glasg) 37:05 Tell us about how you got started producing one video per day 38:10 Tell us a story about a doctor from far away who is influenced by your teaching 40:38 If you could change one thing in residency training today, what would it be? 41:59 Preview of episode 20 43:51 Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:04   Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ.  Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast. Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company's chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Devgan owns and operates CataractCoach.com. Hovanesian consults widely in the ophthalmic field. Kunst is president, chief executive officer and board member at Aurion Biotech. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Slack is president and chief executive officer of The Wyanoke Group. Small is chief executive officer and member of the board of directors for Neurotech. The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.

Der demographische Wandel hat viele Gesichter. Altersbedingte Augenkrankheiten gehören auf jeden Fall dazu. Carl Zeiss Meditec ist genau hier schon heute gut positioniert. Mit Blick auf die kommenden Jahre ist das deutsche Medizintechnik-Unternehmen aber gerade jetzt besonders spannend. Warum das so ist, schreibt Heiko Böhmer im aktuellen Frankfurter Investmentblog. Kapitelmarken: 00:00-02:24 Geschäftsmodell von Carl Zeiss Meditec 02:25-03:33 Marktpotenzial & stetiges Wachstum 03:34-04:16 Eigentümerstruktur bringt Stabilität 04:17-05:46 Burggraben & größter Wachstumstreiber 05:47-06:48 Warum die Aktie jetzt spannend ist? ✅✅✅ Abonnieren Sie hier den Shareholder Value Newsletter: https://www.shareholdervalue.de/newsletter ▶️ Hier geht es zum aktuellen Frankfurter Investmentblog: https://www.shareholdervalue.de/blog/author/heiko-boehmer +++RECHTLICHE HINWEISE+++ https://www.shareholdervalue.de/rechtliche-hinweise

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more. Welcome to the Eyeluminaries podcast :01 Review of episode 17, live from Octane OTF :41 Bausch + Lomb makes a number of big moves under the new Brent Saunders regime 1:40 Mark Baum and Harrow Health have also been making a number of acquisitions 3:59 FDA approves Xdemvy for Demodex blepharitis treatment 5:45 Former CEO of Johnson & Johnson Alex Gorsky elected lead director of Neurotech's board 7:47 John begins new clinical committee for ASCRS, digital 9:32 Julia Haller, MD introduction 11:30 ReST Committee update on intraocular inflammation reported in patients who received Syfovre at the American Society of Retina Specialists annual meeting 13:44 The FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma 14:16 Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration 14:36 How has the latest retina news affected patients and physicians? 14:53 The development of biosimilars 19:50 Discussion on pricing of products 21:57 The evolution and future of residency programs 23:34 Fun with retina drug names 27:15 Preview of episode 19 at OSN New York 29:46 Feedback, questions and guest suggestions at eyeluminaries@healio.com 30:15 Thanks for listening 30:27 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.

ZEISS Optics is a renowned and innovative German company specializing in designing and producing high-quality optical and optoelectronic solutions. With a rich history dating back to its founding in 1846 by Carl Zeiss in Jena, Germany, the company has consistently pushed the boundaries of optical technology.   The company's commitment to innovation has led to significant contributions in lens design, manufacturing techniques, and imaging technologies. ZEISS Optics has a reputation for blending scientific expertise with artistic creativity, resulting in products that cater to both the technical demands and the aesthetic aspirations of professionals and enthusiasts alike.   Throughout its history, ZEISS Optics has played a vital role in shaping the fields of optics, microscopy, and imaging, and it continues to influence how we see and interact with the world around us.   Today, we talk about Zeiss Riflescopes. Where they come from, where they are now, and where are they going in the future. If you're a fan of Zeiss Optics, you'll definitely want to listen in!   Pull up a bench. Therapy is in session.  ***************************************************************** Have questions or suggestions for the show? Drop us a message at GroupTherapy@EuroOptic.com!  Follow us on social media: Facebook.com/eurooptics instagram.com/euroopticltd YouTube.com/EuroOpticltd  Subscribe to our podcast on whatever platform you use to listen to podcasts!

Das Buch zum Podcast? JETZT AUCH ALS HÖRBUCH. Lieber als Newsletter? Geht auch. Buffett hat 1 Siemens und 1 Snapchat an Cash. Der BVB macht wilde Fehler und KPMG schaut weg. Außerdem ist Australien angesagt (Atlassian), aber Sicherheit ist erstmal egal (Fortinet). Achja: Barbie wird Milliardärin. Luxuskaufhäuser, Sport-Discounter und Newcastle United. Passt nicht zusammen? Mike Ashley bringt's zusammen. Die Frasers Group (WKN: A0MK5S) bringt's an die Börse. Nur Newcastle ist raus. Wir sehen immer schlechter. Carl Zeiss Meditec (WKN: 531370) feiert's. Diesen Podcast vom 07.08.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTS with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 16 with Stephen McLeod, MD :28 ·       Preview of episode 17, live at Octane OTS 1:00 ·       Introduce Mark Leahey, president & CEO for the Medical Device Manufacturers Association 1:23 ·       Challenges in medical device 2:19 ·       Is it possible for the government to reduce regulation of medical devices while still protecting patients? 4:32 ·       What is MDMA doing for sustainability? 6:50 ·       What is one issue that device manufacturers need to implement? 9:04 ·       Introduce Brent Saunders, Chairman and CEO of Bausch + Lomb 12:23 ·       What's different about Bausch + Lomb today that wasn't around when you first worked for the company? 13:27 ·       Tell us about other products at Bausch + Lomb. 19:22 ·       Introducing Yari Mitchell, the president of Y Factor Consulting, Inc. 23:31 ·       What have been the most important changes in the ophthalmic industry over the past couple of years? 24:58 ·       What advice would you give to an early-career person? 26:15 ·       Favorite memories of Jim Mazzo 29:14 ·       Introducing Robert Dempsey, CEO and President of AsclepiX Therapeutics 32:10 ·       What was it like to leap from medical sciences to a leadership position? 33:22 ·       Managing a pipeline that includes both retinal and cornea treatments 35:05 ·       How do you establish yourself as a competitor in age-related macular degeneration research in a mature and crowded market with limited resources? 36:10 ·       Creating a retinal treatment delivered via the suprachoroidal route 37:28 ·       The Holland Foundation For Sight Restoration seeking to spread access to eye care for patients and the importance of giving back 38:27 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:00 ·       Thanks for listening 44:19 Robert Dempsey is the CEO and president of AsclepiX Therapeutics. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO of the Medical Device Manufacturers Association. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Yari Mitchell is the president of Y Factor Consulting, Inc. Brent Saunders is the chairman and CEO of Bausch + Lomb. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Dempsey is the president and CEO of AsclepiX Therapeutics. Hovanesian consults widely in the ophthalmic field. Leahey is the president & CEO for the Medical Device Manufacturers Association. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Mitchell is the chief business development officer at AcuFocus and the president of Y Factor Consulting, Inc. Saunders is the chairman and CEO of Bausch + Lomb.

Season 3 Episode 19 - Analog Combo: CONTAX Carl Zeiss Planar T* 50mm F/1.7 Lens w/ the CONTAX ST Another analog combo - this time featuring the legendary glass that is c/y mount Carl Zeiss. Luckily today's episode is not only about lens performance that will blow your mind - but it comes at a quite reasonable price. Yes, today will be all about the often maligned AEJ version of the Zeiss lineup, as well as their somewhat neglected SLRs from the 80s & 90s. Will this under $200 50mm Planar live up to the c/y lenses of renown? Are there any original 1975 era RTS cameras that still fully function? Is the viewfinder on the CONTAX ST a joy to behold? Tune in, turn on - grab a cup of tea - and listen in. Topics: Contax c/y lenses, Contax RTS, Contax 167 MT, Contax ST, CONTAX Carl Zeiss Planar T* 50mm F/1.7  AEJ, MMJ, Rodinal stand development, 50mm primes, Kodak TMAX, Acros 100. https://www.fredmiranda.com/forum/topic/1487249 https://camerapedia.fandom.com/wiki/Contax_RTS  https://cameragx.com/2020/04/04/contax-st-and-vario-sonnar-28-85-worth-the-hype/  --- Send in a voice message: https://podcasters.spotify.com/pod/show/charles-kershenblatt8/message

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 15, live from Eyecelerator :37 ·       Preview of episode 17, live at Octane OTF 1:07s ·       Théa to acquire seven branded ophthalmic products from Akorn 2:17 ·       FDA approves Miebo to treat signs, symptoms of dry eye disease 5:11 ·       OCS-01 eye drops meet primary, secondary endpoints in diabetic macular edema phase 3 trial 8:56 ·       ‘One of my greatest honors': Jim Mazzo awarded Ellis Island Medal of Honor 10:38 ·       Introduction Stephen McLeod, MD 12:14 ·       What's been your biggest challenge transitioning from clinical practice to your current position? 14:16 ·       Where is the AAO going now? 17:50 ·       Prior authorizations are the bane of operational existence. What is AAOs role in reforming this system? 22:59 ·       The future of meetings 30:27 ·       Preview of episode 17 35:44 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:47 ·       Thanks for listening 54:02 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Stephen McLeod, MD, is the CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. McLeod is the CEO of the American Academy of Ophthalmology.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care. ·       Welcome to the Eyeluminaries podcast :00 ·       Preview of episode 15 :32 ·       Review of episode 14, STAAR Surgical :40 ·       Nick Curtis, CEO of Lensar 1:41 ·       Lensar is a unique company with loyal customers. How have you achieved that? 3:21 ·       What are the positives and challenges to not having a large organization as support? 4:09 ·       Where do you see the company and its products evolving over the next 5 years? 8:01 ·       Do you think the company is going to grow because you are taking share? Or because you are taking share and the market is going to grow? 10:06 ·       What is the accelerator for market growth? 10:19 ·       Who's your favorite Chicago team? 12:03 ·       Juliet Bakker, managing director and founder of Longitude Capital 13:11 ·       What makes ophthalmology an appealing specialty to you from an investment and a personal perspective? 14:30 ·       Give a sense of how you see Eyecelerator as an investor. 18:32 ·       What did you learn from failed investments? 21:39 ·       What are the signs of success that you look for? 23:03 ·       Ramin Valian, vice president Eye Care Allergan/AbbVie 24:31 ·       What is happening in ophthalmology at AbbVie? 25:21 ·       What were the key learnings after launching Vuity? 27:52 ·       Does ophthalmology have the same momentum as aesthetics? 30:12 ·       Susan Siw Daniels, PhD, chief scientific officer at Avellino Labs 34:11 ·       Why is your background perfect for Avellino? 35:06 ·       What things did you see transform in other specialties that you see potentially happening in ophthalmology? 38:02 ·       What data are you looking for to expand predictive testing and treatments in eye care in the future? 39:07 ·       How do you get ophthalmologists more involved in genetic testing? 40:30 ·       Julie Schallhorn, MD, MS 43:00 ·       What's new at the Eyecelerator? 44:42 ·       What are the signs of success in a startup company? 47:44 ·       What is your advice for people who want to balance their time with a medical career and personal life? 49:45 ·       Preview of episode 16 53:28 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 53:56 ·       Thanks for listening 54:02 Juliet Bakker is a managing director and founder of Longitude Capital. Nick Curtis is chief executive officer and member of the board of directors at Lensar. Susan Siw Daniels, PhD, is the chief scientific officer at Avellino. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julie Schallhorn, MD, MS, is an assistant professor of ophthalmology at UCSF. Ramin Valian is the vice president of Eye Care Allergan/AbbVie. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bakker serves on the boards of Ceribell, Engogenex, Nalu Medical and RxSight. Curtis is a member of the board of directors for Lensar. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schallhorn sits on the Ophthalmic Technology Assessment Committee for Refractive Surgery for the American Academy of Ophthalmolgy and the Young Eye Surgeons Committee for the American Society of Cataract and Refractive Surgeons.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the new leadership at STAAR Surgical with Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD. •    Welcome to the Eyeluminaries podcast :00 •    Review of episode 13 with Gil Kliman, MD :23 •    Review of episode 12, the Annual Drug Name Awards :52 •    Preview of episode 14 1:20 •    Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD, introduction 1:28 •    Tom: What were the qualities and factors that made you choose Foust and Michna to join the STAAR Surgical team? 3:42 •    Magda: Why STAAR Surgical? 6:07 •    Magda: What can you do to help repair the relationship between STAAR Surgical and the FDA? And what do you hope to change at STAAR? 8:07 •    Warren and Magda: What's the 100-day plan? 9:47  •    Tom: How does STAAR Surgical plan to make the ICL exciting for doctors and patients in the US? 13:17 •    Warren: How do you get physicians excited about the ICL? 16:26 •    Tom and Warren: How do you compete with other companies that have an advantage when it comes to selling STAAR's technology? 18:20 •    What kind of impact would you like to have on STAAR Surgical 3 to 5 years from now? 23:14 •    STAAR Surgical and the Jonas Brothers 28:25 •    Wrap up and thank you, Tom, Warren and Magda 29:51 •    Preview of episode 15 30:04 •    Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:00 •    Thanks for listening 31:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Warren Foust is the chief operating officer at STAAR Surgical. Thomas Frinzi is the president and chief executive officer at STAAR Surgical. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Magda Michna, PhD, is the chief clinical, regulatory and medical affairs officer at STAAR Surgical. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Foust is the chief operating officer at STAAR Surgical. Frinzi is the president and chief executive officer at STAAR Surgical.

In this episode I am talking about the latest news stories that caught my eye this past week. You can find the show notes here. https://liamphotographypodcast.com/episodes/episode-335-carl-zeiss-16mm-wolverine-photo-x-ray-photos-more-234 Remember I now have my own discount code for all Platypod branded products at http://www.platypod.com using my code LD20 you can save 20% off on ALL individual Platypod branded products EXCLUDING Bundles, which are already discounted and Square Jellyfish or Lume Cube branded items. I also now have my own affiliate link for Think Tank Photo, use the link to guy any of their gear, get a free gift and free shipping!!! https://www.thinktankphoto.com/?rfsn=7232819.5f5392&utm_source=refersion&utm_medium=affiliate&utm_campaign=7232819.5f5392 Also be sure to join the Liam Photography Podcast Facebook Group https://www.facebook.com/groups/liamphotographypodcast/ You can reach the show by call or text @ 470-294-8191 to leave a comment or request a topic or guest for the show. Additionally you can email the show @ liam@liamphotographypodcast.com and find the show notes at http://www.liamphotographypodcast.com. You can find my work @ https://www.liamphotography.net and follow me on Instagram, Facebook and Twitter @liamphotoatl. If you like abandoned buildings and history, you can find my project @ http://www.forgottenpiecesofgeorgia.com. and http://www.forgottenpiecesofpennsylvania.com. Please also stop by my Youtube channels Liam Photography Forgotten Pieces of Georgia Project Forgotten Pieces of Pennsylvania Project

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 12 with Richard L. Lindstrom, MD :30 ·       Preview of episode 13 1:35 ·       Gil Kliman, MD, introduction 2:36 ·       History of Silicon Valley Bank 4:25 ·       Silicon Valley Bank's collapse 6:08 ·       Guest welcome 8:07 ·       Was the collapse a surprise? 8:22 ·       Kliman on major themes of this event being how fast it happened and how unprecedented it was for companies 9:34 ·       How many ophthalmic companies have been affected, and what are the next steps for these companies? 10:16 ·       Kliman on the turning point when the FDIC stepped in on Sunday 11:50 ·       Have you had companies report that they have accessed their funds at Silicon Valley Bank? 12:27 ·       Kliman on his experience with Silicon Valley Bank 12:45 ·       What should companies do going forward, and what are you advising companies? 14:17 ·       Kliman on figuring out a new strategy and the unique issue of 90% of depositors being above the $250,000 FDIC threshold 16:13 ·       What is the survival rate for small banks now? 17:31 ·       What do you think the flavor of the room will be at Eyecelerator@ASCRS? 19:20 ·       Kliman's advice for companies to focus on burn rates 20:35 ·       The physician's perspective for supporting innovation and small business 21:54 ·       How strategics can continue to partner with startups using their venture arm 24:04 ·       Information on the Eyecelerator meeting 25:46 ·       Wrap up and thank you, Gil 26:16 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 26:45 ·       Thanks for listening, and preview of episode 14 27:11 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Gil Kliman, MD, is managing partner at InterWest Partners and is co-founder and program director of Eyecelerator. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Kliman is managing partner at InterWest Partners.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.        Welcome to the Eyeluminaries podcast :00        OTF Meeting 01:41        Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04        Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42        The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21        Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24        Best of the year award – Pegcetacoplan 6:49        Near miss award – Beovu (brolucizumab) 8:08        Awful award – Byooviz (ranibizumab-nuna) 8:45        Guest welcome 9:40        Richard L. Lindstrom, MD, introduction 10:31        FDA grants fast track designation for retinitis pigmentosa treatment 10:36        EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14        Amazon launches discount prescription drug service 17:46        Interview with Lindstrom 21:42        What is the biggest innovation in ophthalmology in your career? 22:40        What is coming in the next 10 years? 25:24        What is out there that will get in the way of innovation? 26:54        What advice would you give to residents? 28:35        What advice would you give to entrepreneurs? 30:16        What story can you share about one historical figure in ophthalmology? 31:59        Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14        Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29        Thanks for listening 36:53 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news stories, live from Hawaiian Eye. Welcome to the Eyeluminaries podcast :01 Review of episode 10, the Allergan alumni guests 1:30 Bausch + Lomb announces acquisition of AcuFocus 3:39 Mazzo attributes success to people and the magic of ophthalmology 5:40 Keranova's PhotoEmulsification technique shows promising results 9:25 Centricity CEO discusses latest cataract surgery products 11:04 Orasis submits new drug application for presbyopia drop 12:30 Aldeyra submits NDA for primary vitreoretinal lymphoma treatment 15:27 Iveric Bio submits final part of Zimura new drug application for rolling review 17:30 Tom Frinzi to become CEO of STAAR Surgical 22:37 Wrap up and a preview of episode 12 25:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 27:39 Thanks for listening 28:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

ENTERTAINING SHORT FILMS is a new category on the RPA Network, which features indie short films for your enjoyment! We applaud these creators! In the 1970s a group of teenage girls test their nerve against the legendary Witch Tree, it is told to possess a dark ancient spirit with evil intentions. We shot this using a Panasonic GH4 and a variety of vintage Carl Zeiss lens from the 1960s.